Made in Buch
Excellent basic and clinical research in biomedicine and world-class biotechnology are hallmarks of Campus Berlin-Buch. The objective is to translate scientific findings as rapidly as possible in order to develop new treatments and diagnostic methods.
"Made in Buch" stands for high quality and innovation in the life sciences.
Maya Niethard, MD and Christian Regenbrecht, PhD collaborate in research on sarcomas
Sarcomas comprise a relatively rare class of cancers, with about 4,000 new cases in Germany each year. Particularly young people are often affected. At Helios Hospital Berlin-Buch, around 600 patients with bone and soft tissue sarcomas are treated every year at the certified Sarcoma Center, which is one of the largest in Germany. A distinctive feature of the Center is its research collaboration on sarcomas with the start-up CELLphenomics. Specializing in 3D cell cultures, the biotech company on the Berlin-Buch campus seeks to make even more precisely tailored treatments available to each individual patient. This is made possible with tests on organoids that are derived from small pieces of the tumor tissue.Read more about the Buch success story
Targeted detection of tumor cells
The human immune system is trained to distinguish between “self” and “non-self” and to destroy foreign structures. By means of anchor molecules (receptors) of T cells, it recognizes antigens of bacteria or viruses and thus can target and destroy such invaders. Cancer cells, however, are the body’s own cells, which is why the immune system does not mount an attack but instead tolerates them. A research team led by Professor Thomas Blankenstein has now succeeded in genetically altering human T cells so that their receptors can specifically track and destroy certain tumor cells. More than ten years of research have thus been crowned with success. The start-up T-knife is now developing one of the first T cell receptor gene therapies in Germany on the Berlin-Buch campus using this technology.Lesen Sie mehr zur Bucher Erfolgsgeschichte
Atrial fibrillation therapy
Founded in 2013 as a spin-off of the Max Delbrück Center for Molecular Medicine (MDC), OMEICOS succeeded in bringing its drug candidate for atrial fibrillation from an early preclinical concept to clinical testing in just three years. OMT-28 is a small molecule with heart rhythm-stabilizing and cardioprotective activity. All previous data suggest that the scientists have found a way to treat atrial fi brillation causally for the first time. With classical drugs it is possible to treat the symptoms, but not the underlying heart disease. The active substance is a synthetic analogue of a metabolic product of omega-3 fatty acids, the biological relevance of which has been discovered in years of systematic comparative research at the MDC. The drug candidate OMT-28 could provide millions of patients with a safe and effective treatment option.OMEICOS Therapeutics GmbH
Glycotope GmbH: GlycoExpress ™
Innovative biotechnology in top form
For its GlycoExpressTM (GEX) technology platform the company Glycotope GmbH was awarded the Innovation Prize Berlin-Brandenburg in 2010. The technology platform is used to optimize biotechnologically produced drugs (biotherapeutics).
Through so-called “glycoengineering”, i.e. the optimization of complex glucose chains attached to proteins, cell lines are produced that have excellent biotechnical properties. These are then used to develop and produce much improved drugs, e.g. antibodies for cancer therapy.
GLYCOTOPE is a leading technology and service provider in the fields of glycomics and immunotherapy.
Eckert & Ziegler BEBIG: IsoSeed ®
Targeted, gentle treatment of prostate cancer
Targeted, gentle treatment of prostate cancer
Prostate cancer is one of the most common types of cancer in men. In Europe alone there are approximately 135,000 new cases annually. Brachytherapy has proved to be a highly effective and very gentle form of treatment for early-stage prostate cancer. Using a needle, millimeter-sized, low-level radioactive implants (seeds) are placed in a targeted area of the prostate. They provide optimal dose distribution in the irradiated tissue with minimal adverse effects on the surrounding organs.
LDR brachytherapy is highly effective, well tolerated, and is characterized by a short treatment time and a relatively fast physical recovery. LDR brachytherapy with medical products from Eckert & Ziegler BEBIG as IsoSeed® (individual seeds) or IsoCord® (seed chains) has been successfully performed in clinical practice for more than ten years.
Eckert & Ziegler BEBIG is the European leader in the field of permanent seed implantation and the world’s only provider of the complete range of brachytherapy products.
Forscherferien im Gläsernen Labor
Vorlesungsreihe: Neue Wege in der Biomedizin: Biologie der Flechten – Geheimnisvolle Doppelwesen vor unserer Haustür
CRISPR/Cas: Grundlagen und praktische Anwendung